Victoza gained FDA approval in 2010, for the treatment of Type 2 diabetes, yet only a short time later, adverse reports began coming in to the FDA. Victoza is manufactured by a Danish company, Novo Nordisk; the company was required to conduct a five-year study to determine the risks of pancreatitis, hypoglycemia, serious allergic reactions, pancreatic cancer and thyroid cancer among Victoza patients. Victoza was also approved with the understanding that it would be a second-line defense drug which means it would only be prescribed when other drug treatment was unsuccessful. 

Many of those who have taken the Type 2 diabetic drug, Victoza, may be wondering whether they are entitled to file a Victoza lawsuit to recover expenses related to adverse health symptoms developed after starting the drug. Victoza, manufactured by Novo Nordisk, gained FDA approval in 2010, although there were two FDA pharmacologists and one FDA Clinical Safety Reviewer who were opposed to approving the drug until further studies had been done. This March, a Drug Safety Communication was sent out to alert the public to a potential risk of Victoza in the development of pancreatitis, pancreatic cancer and thyroid cancer.

Victoza, a drug used in the treatment of Type 2 diabetes which received FDA approval in  2010, has suffered serious Victoza safety concerns as more patients are reporting adverse health issues after taking the drug. The advocacy group, Public Citizen, filed a petition with the FDA in April of 2012, requesting that Victoza be removed from the market. The group cited higher-than-normal risks of thyroid cancer, pancreatitis, severe allergic reactions, kidney failure and pancreatic cancer, stating these risks far outweighed the benefits of the drug.

Those patients taking the drug Victoza for the treatment of their Type 2 diabetes are likely to have a number of questions regarding the safety of the drug. Whether the drug causes such serious health problems as pancreatic cancer, thyroid cancer, kidney disease and pancreatitis is currently being debated with a number of studies pointing to these dangers. Several studies have placed the risks of a patient taking Victoza and developing pancreatitis at as much as three times that of those taking an older diabetes drug, and the risks of pancreatic cancer is significantly increased as well. Victoza works by mimicking the actions of incretin hormones in the body.

A recent study of pancreatic cancer among patients taking Victoza, a drug used in the treatment of Type 2 diabetes, reported by eHealthMe and based on FDA reports showed that as of June 14, 2013, 11,308 people have reported serious side effects while taking Victoza. Eighty-three of those patients have developed pancreatic cancer, with over 85% of those 83 people developing the pancreatic cancer within 12 months of beginning the drug. Of these 83 people, 40% were female, and 60% were male with an age range of 50-75.